Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
Chest. 2018 Apr;153(4):825-833. doi: 10.1016/j.chest.2017.12.007. Epub 2017 Dec 20.
The outcome of extracorporeal membrane oxygenation (ECMO) might be influenced by its complications. Only limited information is available regarding the pathologic consequences of ECMO, especially in the era of modern ECMO technology.
We studied the histopathologic findings in autopsy lungs of patients treated with ECMO compared with those without ECMO. Autopsy files were queried for cases with ECMO. An age- and sex-matched control group comprised of patients who died in the ICU without acute respiratory distress syndrome, pneumonia, or ECMO was compared with patients with ECMO for cardiac reason. Histopathology and medical records were reviewed.
Seventy-six patients treated with ECMO (38 men; median age, 40 years) and 47 control patients (23 men; median age, 45 years) were included. Common histologic pulmonary findings in the ECMO group were pulmonary hemorrhage (63.2%), acute lung injury (60.5%), thromboembolic disease (47.4%), calcifications (28.9%), vascular changes (21.1%), and hemorrhagic infarct (21.1%). Pulmonary hemorrhage was associated with longer ECMO duration (median, 7.0 vs 3.5 months; P = .014), acute lung injury with venovenous ECMO (91.7% vs 54.7%; P = .039) and longer ECMO (6.0 vs 4.0 months; P = .044), and pulmonary calcifications with infants (50.0% vs 22.4%; P = .024). Patients with ECMO for cardiac reasons (n = 60) more frequently showed pulmonary hemorrhage (P < .001), diffuse alveolar damage (P = .044), thromboembolic disease (P = .004), hemorrhagic infarct (P = .002), pulmonary calcifications (P = .002), and vascular changes (P = .001) than patients in the non-ECMO group.
Some findings are suspected to be associated with the patient's underlying disease, whereas others might be related to ECMO. Our results provide a better understanding of ECMO-related lung disease and might help to prevent it.
体外膜肺氧合(ECMO)的结果可能受到其并发症的影响。关于 ECMO 的病理后果,只有有限的信息可用,尤其是在现代 ECMO 技术时代。
我们研究了接受 ECMO 治疗的患者与未接受 ECMO 治疗的患者的尸检肺的组织病理学发现。通过尸检文件查询 ECMO 病例。一个年龄和性别匹配的对照组由在 ICU 中死亡但没有急性呼吸窘迫综合征、肺炎或 ECMO 的患者组成,并与因心脏原因接受 ECMO 的患者进行比较。对组织病理学和病历进行了回顾。
纳入了 76 名接受 ECMO 治疗的患者(38 名男性;中位年龄 40 岁)和 47 名对照组患者(23 名男性;中位年龄 45 岁)。ECMO 组常见的组织学肺部发现包括肺出血(63.2%)、急性肺损伤(60.5%)、血栓栓塞性疾病(47.4%)、钙化(28.9%)、血管变化(21.1%)和出血性梗死(21.1%)。肺出血与 ECMO 持续时间较长有关(中位数 7.0 与 3.5 个月;P=0.014),急性肺损伤与静脉-静脉 ECMO 有关(91.7%与 54.7%;P=0.039)和 ECMO 持续时间较长(6.0 与 4.0 个月;P=0.044),肺钙化与婴儿有关(50.0%与 22.4%;P=0.024)。因心脏原因接受 ECMO 治疗的患者(n=60)更常出现肺出血(P<0.001)、弥漫性肺泡损伤(P=0.044)、血栓栓塞性疾病(P=0.004)、出血性梗死(P=0.002)、肺钙化(P=0.002)和血管变化(P=0.001)比非 ECMO 组患者更常见。
一些发现疑似与患者的基础疾病有关,而其他发现可能与 ECMO 有关。我们的结果提供了对 ECMO 相关肺部疾病的更好理解,并可能有助于预防这种疾病。